Alimta
E133650
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
All labels observed (2)
| Label | Occurrences |
|---|---|
| pemetrexed | 3 |
| Alimta canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T1168574 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Alimta Context triple: [Eli Lilly and Company, notableProduct, Alimta]
-
A.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Alimta Target entity description: Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
A.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
antifolate antineoplastic agent
ⓘ
brand name drug ⓘ chemotherapy drug ⓘ |
| hasActiveIngredient | pemetrexed disodium ⓘ |
| hasApprovalAgency |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| hasATCCode | L01BA04 ⓘ |
| hasCommonAdverseEffect |
anemia
ⓘ
diarrhea ⓘ fatigue ⓘ mucositis ⓘ myelosuppression ⓘ nausea ⓘ neutropenia ⓘ rash ⓘ thrombocytopenia ⓘ vomiting ⓘ |
| hasDosageForm | powder for concentrate for solution for infusion ⓘ |
| hasDrugClass |
antifolate
ⓘ
antimetabolite ⓘ |
| hasEffect |
inhibition of DNA synthesis in rapidly dividing cells
ⓘ
inhibition of RNA synthesis in rapidly dividing cells ⓘ |
| hasGenericName |
pemetrexed
ⓘ
linked to:
Alimta
|
| hasInitialApprovalYear | 2004 ⓘ |
| hasINN |
pemetrexed
ⓘ
linked to:
Alimta
|
| hasPregnancyCategory | can cause fetal harm ⓘ |
| hasRouteOfAdministration | intravenous ⓘ |
| hasSeriousAdverseEffect |
interstitial pneumonitis
ⓘ
renal toxicity ⓘ severe bone marrow suppression ⓘ |
| isContraindicatedIn | severe renal impairment ⓘ |
| isEliminatedPrimarilyBy | renal excretion ⓘ |
| isIndicatedAsMonotherapyFor | non-small cell lung cancer ⓘ |
| isIndicatedInCombinationWith | cisplatin ⓘ |
| isManufacturedBy | Eli Lilly and Company ⓘ |
| isMetabolizedBy | non-CYP mediated pathways ⓘ |
| isUsedFor |
locally advanced non-small cell lung cancer
ⓘ
maintenance treatment of non-small cell lung cancer ⓘ malignant pleural mesothelioma ⓘ metastatic non-small cell lung cancer ⓘ non-small cell lung cancer ⓘ second-line treatment of non-small cell lung cancer ⓘ |
| mayRequirePremedicationWith | corticosteroids ⓘ |
| mechanismOfAction | inhibition of folate-dependent enzymes involved in nucleotide synthesis ⓘ |
| requiresSupplementationWith |
folic acid
ⓘ
vitamin B12 ⓘ |
| targetsEnzyme |
dihydrofolate reductase
ⓘ
glycinamide ribonucleotide formyltransferase ⓘ thymidylate synthase ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Alimta Description of subject: Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
Referenced by (5)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: Alimta
subject linked to:
Eli Lilly and Company (former executive roles prior to governorship)